Qiagen Press Release. This is the third CDx test to be approved for EGFR, and it is the second EGFR mutation test for a lung cancer therapeutic released this year (Roche’s COBAS test was released in May as a CDx for erlotinib). Dako’s IHC test was released...
CMAJ: Uneven accessibility to biomarker test for lung cancer. Interesting adoption case study in Canada. EGFR testing is not paid for by the public healthcare system in all provinces (as an aside, I had no idea that there was province-to-province variability in...
This is an interesting example. – Drugs (dabrafenib and trametinib for advanced melanoma) commercialized by GSK – Test (for BRAF mutations) developed and manufactured by bioMerieux Link to article
UK lagging behind with bowel cancer drug test A study funded by Merck Serono (distributors of cetuximab outside of North America; CDx biomarkers for cetuximab = EGFR+ and KRAS-) found that only 44% of all bowel cancer patients in the UK received testing for KRAS...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
